Bangalore, Feb 9: Zydus Lifesciences Ltd. today announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, reporting robust growth across its key businesses.
Financial Highlights:
-
Q3 FY26: Revenue from operations at ₹68,645 mn, up 30% YoY; EBITDA at ₹18,164 mn, up 31% YoY; Net Profit (Adjusted) at ₹11,109 mn, up 9% YoY.
-
9M FY26: Revenue from operations at ₹1,95,614 mn, up 17% YoY; EBITDA at ₹59,207 mn, up 20% YoY; Net Profit (Adjusted) at ₹38,640 mn, up 15% YoY.
-
R&D Investments: ₹6,074 mn in Q3 (8.8% of revenue) and ₹15,750 mn in 9M (8.1% of revenue).
-
Capex (Organic): ₹4,637 mn in Q3 and ₹13,568 mn in 9M.
Business Updates:
-
India Formulations: Revenue at ₹17,094 mn, up 13% YoY; chronic and super specialty segments continue to lead growth.
-
North America Formulations: Revenue at ₹28,043 mn, up 16% YoY; multiple new product launches and approvals, including Zycubo® for Menkes disease.
-
International Markets: Revenue at ₹7,881 mn, up 38% YoY with broad-based regional growth.
-
API Business: Revenue at ₹2,143 mn, up 26% YoY.
-
Consumer Wellness: Revenue at ₹9,578 mn, up 113% YoY with full consolidation of Comfort Click Limited.
-
MedTech: Revenue at ₹2,996 mn, following full consolidation of Amplitude Surgical.
Operational and Compliance Highlights:
-
USFDA inspections completed with EIR status for Jarod injectable (VAI) and Ahmedabad OSD facility (NAI).
-
CE mark approval received for proprietary ‘Andy’ robotic surgical system.
Innovation Pipeline Updates:
-
NCE Research: Preparing NDA filing for Saroglitazar Magnesium with the USFDA.
-
Biotech: Phase III trial approved for second biosimilar antibody drug conjugate in India.
-
Vaccines: Phase II trial initiated for Bivalent Typhoid Conjugate Vaccine; awarded rabies and typhoid vaccine supply tenders for PAHO and UNICEF.
-
US Specialty & Biosimilars: Licensing and commercialization agreements for novel 505(b)(2) oncology product and biosimilar Pembrolizumab; BLA approval for Nufymco® (biosimilar Ranibizumab).
Commenting on the results, Dr. Sharvil Patel, Managing Director, said:
“Our robust performance across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results. Anchored in patient centricity, supported by compliance and an agile supply chain, we remain focused on consistent execution and driving long-term shareholder value.”
Zydus Lifesciences continues to strengthen its pharma, wellness, and medtech portfolios, delivering innovative solutions to global markets while creating sustainable value for shareholders.